JP2015508757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508757A5 JP2015508757A5 JP2014556052A JP2014556052A JP2015508757A5 JP 2015508757 A5 JP2015508757 A5 JP 2015508757A5 JP 2014556052 A JP2014556052 A JP 2014556052A JP 2014556052 A JP2014556052 A JP 2014556052A JP 2015508757 A5 JP2015508757 A5 JP 2015508757A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595902P | 2012-02-07 | 2012-02-07 | |
| US61/595,902 | 2012-02-07 | ||
| US201261625841P | 2012-04-18 | 2012-04-18 | |
| US61/625,841 | 2012-04-18 | ||
| PCT/EP2013/052439 WO2013117647A1 (en) | 2012-02-07 | 2013-02-07 | Mica binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508757A JP2015508757A (ja) | 2015-03-23 |
| JP2015508757A5 true JP2015508757A5 (enExample) | 2016-03-31 |
| JP6405242B2 JP6405242B2 (ja) | 2018-10-17 |
Family
ID=47714068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556052A Active JP6405242B2 (ja) | 2012-02-07 | 2013-02-07 | Ｍｉｃａ結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10577416B2 (enExample) |
| EP (1) | EP2812027A1 (enExample) |
| JP (1) | JP6405242B2 (enExample) |
| CN (1) | CN104244977A (enExample) |
| AU (1) | AU2013218017B2 (enExample) |
| BR (1) | BR112014019611A2 (enExample) |
| CA (1) | CA2862101A1 (enExample) |
| IL (1) | IL233793B (enExample) |
| RU (1) | RU2656183C2 (enExample) |
| SG (1) | SG11201404177PA (enExample) |
| WO (1) | WO2013117647A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2760471T (pt) | 2011-09-30 | 2017-03-22 | Dana Farber Cancer Inst Inc | Péptidos terapêuticos |
| WO2013117647A1 (en) | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
| NZ629816A (en) * | 2013-03-15 | 2017-07-28 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| US10851148B2 (en) | 2013-03-15 | 2020-12-01 | Novelogics Biotechnology, Inc. | Antibodies to MICA and MICB proteins |
| CN106029694A (zh) * | 2013-12-06 | 2016-10-12 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
| CN113491766A (zh) | 2014-03-14 | 2021-10-12 | 达纳－法伯癌症研究所公司 | 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法 |
| DK3227311T3 (da) * | 2014-12-05 | 2022-03-07 | Xyphos Biosciences Inc | Indsættelige, variable fragmenter af antistoffer og modificerede A1- A2-domæner af NKG2D-ligander |
| EP3270937A4 (en) * | 2015-03-26 | 2018-09-12 | The Trustees Of Dartmouth College | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| CN107850596B (zh) | 2015-07-24 | 2020-12-04 | 先天制药公司 | 用于检测组织浸润nk细胞的方法 |
| CN108770343A (zh) * | 2015-12-04 | 2018-11-06 | 达纳－法伯癌症研究所公司 | 用于治疗癌症的使用MICA/Bα3结构域的疫苗接种 |
| WO2017147247A1 (en) * | 2016-02-23 | 2017-08-31 | Pires Eusebio S | Anti-sas1b antibodies and methods of use |
| BR112018068678A2 (pt) | 2016-03-15 | 2019-01-15 | Innate Pharma | anticorpos anti-mica |
| CN107779433A (zh) * | 2016-08-30 | 2018-03-09 | 天津市康婷生物工程有限公司 | 便捷的刺激nk细胞增殖和分化的饲养层制备方法 |
| CN110088137A (zh) * | 2016-10-19 | 2019-08-02 | 诺瓦罗技科斯生物科技有限公司 | 针对mica和micb蛋白的抗体 |
| CN107964041B (zh) * | 2016-10-20 | 2023-08-01 | 中国科学院广州生物医药与健康研究院 | 高稳定性和高亲和力的dmic及其制法 |
| US11555076B2 (en) | 2016-10-29 | 2023-01-17 | Genentech, Inc. | Anti-MIC antibodies and methods of use |
| US11787858B2 (en) | 2016-12-22 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB3 antibodies and methods of use thereof |
| WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| US11421032B2 (en) | 2017-05-22 | 2022-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for inhibition of MICA/B shedding |
| US11447545B2 (en) * | 2017-07-10 | 2022-09-20 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
| WO2019068907A1 (en) * | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| CA3093407A1 (en) * | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| EP3830128A4 (en) * | 2018-07-31 | 2022-08-17 | Cullinan Mica Corp. | ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B-SHEDDING AND METHODS OF USE |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
| WO2021041238A1 (en) * | 2019-08-23 | 2021-03-04 | Northwestern University | Materials and methods for activating antigen-specific t cell responses |
| CN115551887A (zh) * | 2019-12-05 | 2022-12-30 | 维萨列克斯股份有限公司 | 通用细胞疗法的免疫逃逸机制的调节剂 |
| CN111471099B (zh) * | 2020-03-31 | 2022-04-12 | 长沙学院 | MICA胞外区突变体及其筛选的方法、scFv-MICA融合抗体及其制备方法和应用 |
| CN111718416B (zh) * | 2020-06-25 | 2022-04-01 | 菲鹏生物股份有限公司 | 抗硫氧还蛋白的抗体、其应用和诊断试剂盒 |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| CN116547301A (zh) | 2020-08-10 | 2023-08-04 | 先天制药公司 | 使用抗体进行的细胞表面mica和micb检测 |
| CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业（苏州）有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| CN115611982B (zh) * | 2021-07-14 | 2024-05-10 | 浙江大学 | 一种抗人MICA/Bα3区的单克隆抗体及其应用 |
| CN114369161B (zh) * | 2021-12-28 | 2023-06-23 | 合肥天港免疫药物有限公司 | Mica抗体及其应用 |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| CN118027195B (zh) * | 2023-05-06 | 2025-07-04 | 合肥天港免疫药物有限公司 | 亲和力成熟的mica抗体及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1996030511A1 (en) * | 1995-03-29 | 1996-10-03 | The Immunogenetics Research Foundation Incorporated | Polymorphic and multicopy members of mhc gene families |
| CA2275141A1 (en) | 1996-10-29 | 1998-05-07 | Thomas Spies | Cell stress regulated human mhc class i gene |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CA2483343A1 (en) * | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
| WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| JP2007536932A (ja) | 2004-05-10 | 2007-12-20 | マクロジェニクス，インコーポレーテッド | ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| WO2006133148A2 (en) | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
| HUE029465T2 (en) | 2005-08-10 | 2017-02-28 | Macrogenics Inc | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20070248607A1 (en) | 2005-11-03 | 2007-10-25 | Thomas Spies | Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells |
| FR2894982A1 (fr) | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
| ES2395842T3 (es) | 2006-01-17 | 2013-02-15 | Synthon Biopharmaceuticals B.V. | Composiciones y métodos para la humanización y optimización de N-glicanos en plantas |
| EP1999470A4 (en) | 2006-03-10 | 2009-08-19 | Macrogenics Inc | IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| CA2656224C (en) | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| CA2665090A1 (en) * | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating mica-related disorders |
| CA3011859A1 (en) * | 2007-04-23 | 2008-10-30 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| PT2760471T (pt) * | 2011-09-30 | 2017-03-22 | Dana Farber Cancer Inst Inc | Péptidos terapêuticos |
| WO2013117647A1 (en) | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
| BR112018068678A2 (pt) | 2016-03-15 | 2019-01-15 | Innate Pharma | anticorpos anti-mica |
-
2013
- 2013-02-07 WO PCT/EP2013/052439 patent/WO2013117647A1/en not_active Ceased
- 2013-02-07 EP EP13704064.8A patent/EP2812027A1/en not_active Ceased
- 2013-02-07 JP JP2014556052A patent/JP6405242B2/ja active Active
- 2013-02-07 SG SG11201404177PA patent/SG11201404177PA/en unknown
- 2013-02-07 RU RU2014131317A patent/RU2656183C2/ru active
- 2013-02-07 CA CA2862101A patent/CA2862101A1/en not_active Abandoned
- 2013-02-07 CN CN201380017820.5A patent/CN104244977A/zh active Pending
- 2013-02-07 BR BR112014019611A patent/BR112014019611A2/pt not_active Application Discontinuation
- 2013-02-07 AU AU2013218017A patent/AU2013218017B2/en not_active Ceased
- 2013-02-07 US US14/377,274 patent/US10577416B2/en not_active Expired - Fee Related
-
2014
- 2014-07-24 IL IL233793A patent/IL233793B/en active IP Right Grant
-
2020
- 2020-02-28 US US16/804,705 patent/US20200299380A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7303314B2 (ja) | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 | |
| TWI664289B (zh) | 針對細胞內抗原之單域抗體 | |
| JP2020023523A5 (enExample) | ||
| US10925969B2 (en) | Anti-BCMA polypeptides and proteins | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| JP2017505622A5 (enExample) | ||
| CN110945120A (zh) | 测量纳米药物中受体-配体相互作用的效力的测定 | |
| JP2019531084A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| CN112119099A (zh) | 三特异性抗原结合蛋白 | |
| RU2014131317A (ru) | Связывающие mica агенты | |
| RU2019102393A (ru) | Гуманизированные антитела к фактору d и их применения | |
| TW201643193A (zh) | 一種抗ｐｄ－１的單克隆抗體及其獲得方法 | |
| JP2016539096A5 (enExample) | ||
| JP2017527275A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2010500005A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2017512838A5 (enExample) | ||
| FI3443010T3 (fi) | Uusia anti-sirp -vasta-aineita ja niiden terapeuttisia sovelluksia | |
| JP2020503841A5 (enExample) | ||
| WO2019144677A1 (zh) | 抗ox40抗体及其用途 | |
| CN110475788A (zh) | 抗ceacam1抗体及其应用 | |
| JP2015519355A5 (enExample) |